ClinicalTrials.gg
CompletedNCT04892706Updated Oct 30, 2025Results posted

Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel

A Phase 2 interventional study of IDP-126 Gel and IDP-126 Vehicle Gel in Acne Vulgaris, sponsored by Bausch Health Americas, Inc.. Completed at 42 sites in 3 countries. Open to participants aged 12 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
686
Allocation
Randomized
Ages
12 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Acne Vulgaris by Bausch Health Companies Inc. — 1 open to participants now, 1 under way, none of them phase 3. Acne Vulgaris · Bausch Health Companies Inc..

Enrollment
10th of 35
686 · median 247
Started
2021
the only one that year
Phase 2
10 of 36
none open now
Registered
34th of 36
by date

Among the 36 studies in Acne Vulgaris by Bausch Health Companies Inc., this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is the only one that started in 2021, is one of 10 in phase 2, and was the 34th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 36 studies in Acne Vulgaris by Bausch Health Companies Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Acne Vulgaris by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

The safety and efficacy of once daily application of IDP 126 Gel will be compared to Epiduo® Forte and IDP-126 Vehicle Gel.

Read the detailed description

This is a multicenter, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, tolerability, and efficacy of IDP-126 Gel in comparison with Epiduo® Forte gel and IDP-126 Vehicle Gel at Weeks 2, 4, 8, and 12. To be eligible for the study, subjects must be at least 12 years of age and have a clinical diagnosis of moderate to severe acne (defined as an Evaluator's Global Severity Score [EGSS] of 3 or 4), presenting with 30-100 inflammatory facial lesions (papules, pustules, and nodules), 35-150 non-inflammatory facial lesions (open and closed comedones), and ≤ 2 facial nodules.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
12 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 12 years of age and older.
  • Written and verbal must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
  • Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.
  • Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100.
  • Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150.
  • Subjects with 2 or fewer facial nodules.

Exclusion criteria

Exclusion Criteria:

  • Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, rosacea, gram negative folliculitis, dermatitis, eczema.
  • Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
  • Subjects with more than 2 facial nodules.
  • Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.
  • Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study.
  • Treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area.
  • Subjects who have not undergone specified (s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area.
  • Subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications.
  • Subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
686 participants (actual)

Study arms

  • Experimental
    IDP-126 Gel

    IDP-126 Gel (clindamycin phosphate 1.2%, BPO 3.1%, and adapalene 0.15%), applied topically to the face once daily for 12 weeks

    Drug: IDP-126 Gel

  • Placebo comparator
    IDP-126 Vehicle Gel

    IDP-126 Vehicle Gel applied once daily for 12 weeks

    Drug: IDP-126 Vehicle Gel

  • Active comparator
    Epiduo® Forte Gel

    Epiduo® Forte Gel (adapalene 0.3%/ 2.5% BPO) applied once daily for 12 weeks

    Drug: Epiduo® Forte Gel

Interventions

  • Gel applied to face once daily in the evening.

    Also known as: IDP-126

  • DrugIDP-126 Vehicle Gel

    Gel applied to face once daily in the evening.

    Also known as: Vehicle

  • DrugEpiduo® Forte Gel

    Gel applied to face once daily in the evening.

    Also known as: Epiduo® Forte

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline to Week 12 in Lesion Counts.

    Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.

    Time frame: Baseline to Week 12

  2. Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.

    The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 30, 2025

Participant flow

Participant flow — Overall Study
MilestoneIDP-126 GelIDP-126 Vehicle GelEpiduo® Forte Gel
Started230228228
Completed201196182
Not completed293246

Outcome measures

PrimaryAbsolute Change From Baseline to Week 12 in Lesion Counts.

Inflammatory and non-inflammatory lesion counts were collected starting from the Baseline Visit.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · lesion counts
Absolute Change From Baseline to Week 12 in Lesion Counts.
lesion countsIDP-126 GelIDP-126 Vehicle GelEpiduo® Forte Gel
Absolute Change From Baseline to Week 12 in Lesion Counts.-29.9 ± 11.43-19.7 ± 13.11-27.9 ± 12.16
PrimaryPercentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.

The Evaluator's Global Severity Score has grades for acne severity of 0 (Clear), 1 (Almost Clear), 2 (Mild), 3 (Moderate), and 4 (Severe), with higher scores indicating worse severity.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.
participantsIDP-126 GelIDP-126 Vehicle GelEpiduo® Forte Gel
Percentage of Subjects Who Achieve at Least a Two-grade Reduction From Baseline and Are "Clear" or "Almost Clear" at Week 12 in the Evaluator's Global Severity Score.1184174

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IDP-126 Gel0/230 (0%)1/230 (0.4%)23/230 (10%)
IDP-126 Vehicle Gel0/228 (0%)0/228 (0%)0/228 (0%)
Epiduo® Forte Gel0/226 (0%)0/226 (0%)16/226 (7.1%)
Most frequent serious events
Most frequent serious events
EventIDP-126 GelIDP-126 Vehicle GelEpiduo® Forte Gel
Motor Vehicle AccidentInjury, poisoning and procedural complications1/2300/2280/226
Most frequent other events
Most frequent other events
EventIDP-126 GelIDP-126 Vehicle GelEpiduo® Forte Gel
Application Site PainGeneral disorders23/2300/22816/226

Baseline characteristics

Age, Continuous
Age, Continuous(years)IDP-126 GelIDP-126 Vehicle GelEpiduo® Forte GelTotal
Median17.5 (12 to 56)17 (12 to 51)18 (12 to 51)17 (12 to 56)
Sex: Female, Male
Sex: Female, Male(Participants)IDP-126 GelIDP-126 Vehicle GelEpiduo® Forte GelTotal
Female140131135406
Male909791278
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IDP-126 GelIDP-126 Vehicle GelEpiduo® Forte GelTotal
American Indian or Alaska Native0303
Asian16271962
Native Hawaiian or Other Pacific Islander0000
Black or African American24282678
White179160165504
More than one race741122
Unknown or Not Reported46515
Baseline Evaluator's Global Severity Score
Baseline Evaluator's Global Severity Score(Participants)IDP-126 GelIDP-126 Vehicle GelEpiduo® Forte GelTotal
Moderate201204198603
Severe29242881
08

Study locations

42 sites
  • Bausch Site 134
    Bryant, Arkansas 72022, United States
  • Bausch Site 118
    Rogers, Arkansas 72758, United States
  • Bausch Site 110
    Fremont, California 94538, United States
  • Bausch Site 101
    Manhattan Beach, California 90266, United States
  • Bausch Site 106
    San Diego, California 92123, United States
  • Bausch Site 112
    San Diego, California 92123, United States
  • Bausch Site 128
    San Diego, California 92123, United States
  • Bausch Site 105
    Boynton Beach, Florida 33437, United States
  • Bausch Site 126
    Clearwater, Florida 33761, United States
  • Bausch Site 135
    North Miami Beach, Florida 33162, United States
  • Bausch Site 143
    Sanford, Florida 32771, United States
  • Bausch Site 102
    Tampa, Florida 33607, United States
  • Bausch Site 104
    West Palm Beach, Florida 33401, United States
  • Bausch Site 122
    West Palm Beach, Florida 33406, United States
  • Bausch Site 124
    Newnan, Georgia 30263, United States
  • Bausch Site 127
    Boise, Idaho 83704, United States
  • Bausch Site 129
    Louisville, Kentucky 40241, United States
  • Bausch Site 139
    Mandeville, Louisiana 70448, United States
  • Bausch Site 121
    Metairie, Louisiana 70006, United States
  • Bausch Site 116
    Rockville, Maryland 20850, United States
  • Bausch Site 103
    Brighton, Massachusetts 21350, United States
  • Bausch Site 120
    New Brighton, Minnesota 55112, United States
  • Bausch Site 108
    Las Vegas, Nevada 89148, United States
  • Bausch Site 119
    New York, New York 10022, United States
  • Bausch Site 133
    New York, New York 10075, United States
  • Bausch Site 142
    High Point, North Carolina 27262, United States
  • Bausch Site 109
    Dublin, Ohio 43016, United States
  • Bausch Site 117
    Oklahoma City, Oklahoma 73112, United States
  • Bausch Site 107
    Gresham, Oregon 97030, United States
  • Bausch Site 114
    Nashville, Tennessee 37215, United States
  • Bausch Site 111
    Austin, Texas 78759, United States
  • Bausch Site 132
    Houston, Texas 77098, United States
  • Bausch Site 123
    Pflugerville, Texas 78660, United States
  • Bausch Site 137
    Spokane, Washington 99202, United States
  • Bausch Site 136
    Kortrijk, Belgium
  • Bausch Site 140
    Maldegem, Belgium
  • Bausch Site 138
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Bausch Site 125
    Markham, Ontario L3P 1X3, Canada
  • Bausch Site 141
    Oakville, Ontario L6J 7W5, Canada
  • Bausch Site 115
    Peterborough, Ontario K91 5K2, Canada
  • Bausch Site 130
    Waterloo, Ontario N2J 1C4, Canada
  • Bausch Site 113
    Saint-Jérôme, Quebec J7Z 7E2, Canada
09

References and documents

Publications

  • Gold M, Lain T, Harper JC, Baldwin H, Guenin E, Stein Gold L. Efficacy and Safety of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel: Post Hoc Analysis by Baseline Disease Severity. Dermatol Ther (Heidelb). 2025 Jul;15(7):1867-1882. doi: 10.1007/s13555-025-01440-z. Epub 2025 May 16. PubMed 40377868 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

Results were first posted in Oct 2025, 3 years 1 month after primary completion. A results delay was requested in Aug 2023.

Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 15 months is above that.

Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2021
First posted
May 19, 2021
StartActual
Jun 11, 2021
Primary completionActual
Sep 28, 2022
CompletionActual
Sep 28, 2022
Results delay requested
Aug 31, 2023
Results first posted
Oct 30, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04892706
Responsible party
Sponsor
First posted
May 19, 2021
Start date
Jun 11, 2021
Primary completion
Sep 28, 2022
Completion
Sep 28, 2022
Results posted
Oct 30, 2025
Last update
Oct 30, 2025

Study contacts

Varsha Bhatt
study director · Bausch Health Americas, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IDP-126

Start the discussion